These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37212336)

  • 1. Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy.
    Deng X; Shen Y; Yi M; Zhang C; Zhao B; Zhong G; WeiyangLou ; Xue D; Leng Q; Ding J; Zhao R; Jia W; Dong C; Dai Z
    J Med Virol; 2023 May; 95(5):e28768. PubMed ID: 37212336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes.
    Shen Y; Song W; Lin D; Zhang X; Wang M; Li Y; Yang Z; Guo S; Wang Z; Sheng J; Murad Y; Ding J; Lou Y; Pan X; Wu Z; Zhao R; Jia W; Bai X; Liang T
    J Med Virol; 2023 Jan; 95(1):e28108. PubMed ID: 36042555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus.
    Ding J; Murad YM; Sun Y; Lee IF; Samudio I; Liu X; Jia WW; Zhao R
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes.
    Chouljenko DV; Ding J; Lee IF; Murad YM; Bu X; Liu G; Delwar Z; Sun Y; Yu S; Samudio I; Zhao R; Jia WW
    Biomedicines; 2020 Nov; 8(11):. PubMed ID: 33182232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.
    Bourgeois-Daigneault MC; St-Germain LE; Roy DG; Pelin A; Aitken AS; Arulanandam R; Falls T; Garcia V; Diallo JS; Bell JC
    Breast Cancer Res; 2016 Aug; 18(1):83. PubMed ID: 27503504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
    Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
    Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
    Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
    Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor immune response mediated by paclitaxel-conjugated nanohybrid oncolytic adenovirus with dendritic cell therapy.
    Kim IW; Yoon AR; Hong J; Kasala D; Yun CO
    Front Immunol; 2024; 15():1355566. PubMed ID: 38835775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Herpes Simplex Virus Type 2 Can Effectively Inhibit Colorectal Cancer Liver Metastasis by Modulating the Immune Status in the Tumor Microenvironment and Inducing Specific Antitumor Immunity.
    Zhang W; Zeng B; Hu X; Zou L; Liang J; Song Y; Liu B; Liu S
    Hum Gene Ther; 2021 Feb; 32(3-4):203-215. PubMed ID: 33176492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model.
    Kuryk L; Mathlouthi S; Wieczorek M; Gad B; Rinner B; Malfanti A; Mastrotto F; Salmaso S; Caliceti P; Garofalo M
    Eur J Pharm Biopharm; 2024 Jun; 199():114300. PubMed ID: 38697488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oncolytic HSV-1 armed with Visfatin enhances antitumor effects by remodeling tumor microenvironment against murine pancreatic cancer.
    Zhao J; Wang H; Chen J; Wang C; Gong N; Zhou F; Li X; Cao Y; Zhang H; Wang W; Zheng H; Zhang C
    Biochem Biophys Res Commun; 2024 Jul; 718():149931. PubMed ID: 38723415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.
    Kasala D; Lee SH; Hong JW; Choi JW; Nam K; Chung YH; Kim SW; Yun CO
    Biomaterials; 2017 Nov; 145():207-222. PubMed ID: 28869866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
    Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
    Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.